New Findings at ASCO22 Underscore Potential of Eisai’s First Antibody-Drug Conjugate
Richard Woodman, MD, Chief Clinical Officer, Oncology Business Group at Eisai, discusses notable presentations on the antibody-drug conjugate co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202), at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Richard Woodman, M.D., is Chief Clinical Officer (CCLO) for the Oncology Business Group at Eisai Inc. In this role, he has full oversight and responsibility for the strategic and operational leadership of the company’s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He is a member of the company’s global Oncology Executive Leadership team, in addition to serving on the Board of Directors at H3 Biomedicine, the wholly owned precision oncology research and development subsidiary of Eisai.
Dr. Woodman, who has 20 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, leads the clinical team’s development of Eisai’s next generation oncology products and is accountable for the design of protocols and implementation of all oncology clinical trials. He also oversees all collaboration development projects with partner companies.
